Kymera Therapeutics

A New Wave of Transformational Therapies

Our Focused Path from Target ID to Patients

Since our founding in 2016, Kymera has been singularly focused on the development and application of industry-leading tools to identify E3 ligases and ligands and map the complex processes involved in protein degradation. With increasing command of E3 biology, proprietary tools and predictive modeling capabilities, we can enhance the speed, efficiency and scalability of our pipeline to deliver novel protein degrader therapies.

Today, Kymera is swiftly mobilizing by leveraging our knowledge and pre-clinical data packages to rapidly advance multiple drug candidate programs in oncology and immunology, with an eye on other therapeutics areas as well. We are pursuing a number of targets and pathways that have been largely undruggable. These are first-in-class protein degrader therapies with the potential to deliver truly breakthrough therapies for patients with limited to no known treatment options.

Oncology
Pathway Target
IL–1R / TLR IRAK4 (scaffolding kinase)
Discovery Preclinical Clinical
KYM-001
JAK/STAT STAT3 (transcription factor)
Discovery Preclinical Clinical
Epigenetics Undisclosed
Discovery Preclinical Clinical
Multiple E3 ligase Various undisclosed
Discovery Preclinical Clinical
Inflammation/Immunology
Pathway Target
IL–1R / TLR IRAK4 (scaffolding kinase)
Discovery Preclinical Clinical
JAK/STAT STAT3 (transcription factor)
Discovery Preclinical Clinical
BCR / TCR Undisclosed
Discovery Preclinical Clinical
Oncology
Pathway Target Discovery Preclinical Clinical
IL–1R / TLR IRAK4 (scaffolding kinase) KYM-001
JAK/STAT STAT3 (transcription factor)
Epigenetics Undisclosed
Multiple E3 ligase
Various undisclosed
Inflammation/Immunology
Pathway Target Discovery Preclinical Clinical
IL–1R / TLR IRAK4 (scaffolding kinase)
JAK/STAT STAT3 (transcription factor)
BCR / TCR Undisclosed

A First Target: IRAK4

Our lead candidate addresses IRAK4, a key component of a signaling pathway implicated in the pathophysiology of multiple diseases, including cancer, autoimmune, and inflammatory disorders. Kinase inhibitors have been developed to address this target, but with limited efficacy. Pre-clinical studies of Kymera’s novel oral small molecule degrader, KYM-001, to treat MYD88-drive B cell lymphomas, led to highly selective degradation of IRAK4 and tumor regression both alone and in combination with BTK inhibition. Unlike conventional kinase inhibitors, our degrader removes both the kinase and scaffolding function of IRAK4 to block Myddosome signaling and induce tumor regression.

In addition, across multiple models of inflammation, IRAK4 degradation, but not inhibition, fully reverses inflammation in both human cells and disease models. These desirable properties position our IRAK4 degrader program as a transformative therapeutic solution across inflammatory diseases.

Kymera CMO Jared Gollob explains IRAK4 | Length: 0:55